DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 31.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 215,738 shares of the medical device company’s stock after acquiring an additional 51,275 shares during the quarter. Handelsbanken Fonder AB owned 0.06% of DexCom worth $16,778,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Jennison Associates LLC increased its stake in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after acquiring an additional 6,544,102 shares during the period. Congress Asset Management Co. increased its stake in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after acquiring an additional 1,332,522 shares during the period. Westfield Capital Management Co. LP grew its position in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares during the period. Two Sigma Advisers LP grew its position in DexCom by 182.7% during the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after buying an additional 739,000 shares during the period. Finally, Intech Investment Management LLC grew its position in DexCom by 2,083.0% during the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after buying an additional 369,587 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DXCM shares. Raymond James lowered their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada lowered their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Oppenheimer lowered their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $99.06.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,083 shares of company stock valued at $3,309,794. Insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $88.78 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $34.69 billion, a price-to-earnings ratio of 62.08, a PEG ratio of 2.31 and a beta of 1.14. The company’s 50 day simple moving average is $83.26 and its 200 day simple moving average is $75.94. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.